Platelet Activation Markers in Pediatric Cardiac Surgery
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Effect of Cardiopulmonary Bypass on Platelet Activation Markers Such as Platelet Factor 4 and Transforming Growth Factor B, in Pediatric Cardiac Surgery|
|Study Start Date:||February 2007|
|Study Completion Date:||February 2009|
|Primary Completion Date:||February 2009 (Final data collection date for primary outcome measure)|
This research is being done because we would like to learn more about platelet dysfunction in children undergoing cardiopulmonary bypass.
It has been an established fact that cardiopulmonary bypass causes dysfunction in platelets. Activation of platelets during cardiopulmonary bypass is implicated as being a major factor in causing platelet dysfunction.
For all participants, approximately 3.15 ml of blood will be collected in special tubes called CTAD tubes, before and after cardiopulmonary bypass (6.30ml in total). This amount of blood draw is well within the guidelines of NIH (National Institute of Health).
Enzyme-linked immunosorbent assay (ELISA) will be performed using this plasma to make quantitative assessment of Platelet factor 4 and Transforming growth factor beta.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00450151
|United States, New York|
|NewYork-Presbyterian Hospital-Weill Cornell Medical College|
|New York City, New York, United States, 10065|
|Principal Investigator:||Aarti Sharma, MD||Weill Medical College-New York Presbyterian Hospital|